Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abandon, Acura, addressing, appellate, authentic, AZ, Bryan, buproprion, CID, commerce, counterfeit, counterfeiting, Depomed, encryption, expressly, faster, forecast, Gabapentin, GDFUA, GDUFA, GMP, Gralise, Hamburg, hiring, IMS, IND, indistinguishable, ineffective, instance, insufficient, intervened, lengthy, Master, mistakenly, modest, notified, older, outbound, Oxecta, password, placebo, preclude, ProAmatine, psychiatric, psychotherapeutic, Ranbaxy, RAR, ready, reargue, redirected, referenced, rehearing, resubmit, resubmitted, RYTARY, satisfactory, stolen, stored, surveillance, symptomatic, thirty, ThoRx, TM, tolmar, TRICARE, unique, unsafe, Valeant, visually, voluntarily, voluntary, withdrew, withheld
Removed:
AB, Abbott, absence, adding, aI, Ala, Alabama, allege, Anderson, assert, Baldwin, bioavailability, Brown, Calif, Carbatrol, Carbonate, Carolina, Chilcott, Chloride, Cir, collected, commit, consolidate, contrary, convert, County, Crt, cumulative, Cymbalta, Daiichi, deficit, denominator, depression, description, Detrol, disorder, Dist, doryx, Duloxetine, Eastern, Elan, elapsed, Eli, exploratory, facilitate, Fla, Florida, Fludrocortisone, formation, Fournier, fraction, Fremont, gave, Genzyme, grew, Hanover, heard, Henchenski, Hyclate, hyperactivity, impacted, Indiana, inPfizer, Ireland, Jefferson, Jordan, LA, Latvala, Leighty, Lilly, Lipram, Louisiana, Maryland, Mayne, MDL, misrepresentation, Morgan, multidistrict, multiplying, negligent, numerator, Ohio, Oklahoma, ordered, Oxybutynin, Pa, Parish, Pharmacia, Pilocarpine, plaintiff, prepayment, pro, Promethazine, promissory, prospectively, Pty, published, rata, ratably, Renagel, Renvela, repay, repayment, repurchased, retroactive, reversal, Rosenfeld, Sankyo, stay, steadily, stipulated, structure, subordinated, Superior, Tartrate, Tex, thePfizercourt, tied, Tier, titledKelly, Tolterodine, training, tricor, UL, unenforceability, unspecified, Upjohn, utilizing, vacated, Vogel, Wachovia, Warner, Washington, Watson, Weber, Welchol, xii
Filing tables
Filing exhibits
Related press release
IPXL similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Impax Laboratories, Inc. (the “Company”) for the fiscal year ended December 31, 2012 (the “Report”), Larry Hsu, President and Chief Executive Officer, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code), that:
| (1) | the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: February 26, 2013 | By: | /s/ Larry Hsu, Ph.D. | |
| Larry Hsu, Ph.D. | |||
| President and Chief Executive Officer | |||
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code) and is not being filed as part of the Report or as a separate disclosure document.